Home > Publications Database > Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice > print

001     153278
005     20240221115046.0
024 7 _ |a pmc:PMC7338806
|2 pmc
024 7 _ |a 10.15252/emmm.201911803
|2 doi
024 7 _ |a 1715-4684
|2 ISSN
024 7 _ |a 1757-4676
|2 ISSN
024 7 _ |a 1757-4684
|2 ISSN
024 7 _ |a altmetric:83751758
|2 altmetric
024 7 _ |a pmid:32510847
|2 pmid
037 _ _ |a DZNE-2020-01275
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wilke, Carlo
|0 P:(DE-2719)2814101
|b 0
|e First author
|u dzne
245 _ _ |a Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice
260 _ _ |a Heidelberg
|c 2020
|b EMBO Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1708433297_6807
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a With molecular treatments coming into reach for spinocerebellar ataxia type 3 (SCA3), easily accessible, cross‐species validated biomarkers for human and preclinical trials are warranted, particularly for the preataxic disease stage. We assessed serum levels of neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in ataxic and preataxic subjects of two independent multicentric SCA3 cohorts and in a SCA3 knock‐in mouse model. Ataxic SCA3 subjects showed increased levels of both NfL and pNfH. In preataxic subjects, NfL levels increased with proximity to the individual expected onset of ataxia, with significant NfL elevations already 7.5 years before onset. Cross‐sectional NfL levels correlated with both disease severity and longitudinal disease progression. Blood NfL and pNfH increases in human SCA3 were each paralleled by similar changes in SCA3 knock‐in mice, here also starting already at the presymptomatic stage, closely following ataxin‐3 aggregation and preceding Purkinje cell loss in the brain. Blood neurofilaments, particularly NfL, might thus provide easily accessible, cross‐species validated biomarkers in both ataxic and preataxic SCA3, associated with earliest neuropathological changes, and serve as progression, proximity‐to‐onset and, potentially, treatment‐response markers in both human and preclinical SCA3 trials.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 1
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 2
588 _ _ |a Dataset connected to CrossRef
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Intermediate Filaments: chemistry
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: blood
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Prodromal Symptoms
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
693 _ _ |0 EXP:(DE-2719)ESMI-20140101
|5 EXP:(DE-2719)ESMI-20140101
|e European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative
|x 0
700 1 _ |a Haas, Eva
|b 1
700 1 _ |a Reetz, Kathrin
|b 2
700 1 _ |a Faber, Jennifer
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Garcia‐Moreno, Hector
|b 4
700 1 _ |a Santana, Magda M
|b 5
700 1 _ |a Warrenburg, Bart
|b 6
700 1 _ |a Hengel, Holger
|0 P:(DE-2719)2811940
|b 7
|u dzne
700 1 _ |a Lima, Manuela
|b 8
700 1 _ |a Filla, Alessandro
|b 9
700 1 _ |a Durr, Alexandra
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Melegh, Bela
|b 11
700 1 _ |a Masciullo, Marcella
|b 12
700 1 _ |a Infante, Jon
|b 13
700 1 _ |a Giunti, Paola
|b 14
700 1 _ |a Neumann, Manuela
|0 P:(DE-2719)2810592
|b 15
|u dzne
700 1 _ |a Vries, Jeroen
|b 16
700 1 _ |a Pereira de Almeida, Luis
|0 0000-0001-5831-3307
|b 17
700 1 _ |a Rakowicz, Maria
|b 18
700 1 _ |a Jacobi, Heike
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Schüle, Rebecca
|0 P:(DE-2719)2812018
|b 20
|u dzne
700 1 _ |a Kaeser, Stephan A
|0 P:(DE-2719)9000387
|b 21
|u dzne
700 1 _ |a Kuhle, Jens
|b 22
700 1 _ |a Klockgether, Thomas
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 24
|u dzne
700 1 _ |a Barro, Christian
|b 25
700 1 _ |a Hübener‐Schmid, Jeannette
|b 26
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 27
|u dzne
700 1 _ |a Deuschle, Christian
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Stransky, Elke
|0 P:(DE-HGF)0
|b 29
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-HGF)0
|b 30
700 1 _ |a Schulz, Jörg B
|b 31
700 1 _ |a Baliko, Laszlo
|b 32
700 1 _ |a Gaalen, Judith
|b 33
700 1 _ |a Raposo, Mafalda
|b 34
700 1 _ |a Jeromin, Andreas
|b 35
773 _ _ |a 10.15252/emmm.201911803
|g Vol. 12, no. 7
|0 PERI:(DE-600)2485479-7
|n 7
|p e11803
|t EMBO molecular medicine
|v 12
|y 2020
|x 1757-4684
856 4 _ |u https://www.embopress.org/doi/full/10.15252/emmm.201911803
856 4 _ |u https://pub.dzne.de/record/153278/files/DZNE-2020-01275.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/153278/files/DZNE-2020-01275.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:153278
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2814101
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811940
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2810592
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2812018
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)9000387
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2811275
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 2
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO MOL MED : 2021
|d 2022-11-29
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EMBO MOL MED : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-07-19T13:19:31Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-07-19T13:19:31Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review, Double blind peer review
|d 2021-07-19T13:19:31Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-04
920 1 _ |0 I:(DE-2719)1240005
|k Core ICRU
|l Core ICRU
|x 0
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 1
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 2
920 1 _ |0 I:(DE-2719)1210003
|k AG Neumann
|l Molecular Neuropathology of Neurodegenerative Diseases
|x 3
920 1 _ |0 I:(DE-2719)5000024
|k AG Maetzler
|l Functional Neurogeriatrics
|x 4
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 5
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 6
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 7
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1210003
980 _ _ |a I:(DE-2719)5000024
980 _ _ |a I:(DE-2719)1210001
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)5000005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21